Genrix (shanghai) Biopharmaceutical Co., Ltd.

This study tests a new medicine called GR2301, given as shots under the skin, together with light therapy for people with vitiligo (a condition that causes white patches on the skin). The trial has two parts: first, finding the right dose, then testing how well it works. About 11…

This study tests an injection called GR1802, given alongside usual allergy treatments, to see if it can better control symptoms like sneezing, runny nose, and itchy eyes in people with seasonal allergic rhinitis (hay fever). About 144 adults who have had poor symptom control with…

This early-stage trial tests the safety and tolerability of GR2301, an antibody that targets IL15, in 36 healthy adults in China. Participants receive multiple rising doses to see how the drug moves through the body and whether it triggers an immune response. The goal is to gathe…

This early-stage trial tests a single injection of GR2301, an antibody that targets IL15, in 36 healthy adults in China. The main goal is to check safety and how the body processes the drug. Participants are randomly assigned to receive either GR2301 or a placebo, and are monitor…